The Journal of Headache and Pain
Volume 10, Number 5 / October, 2009
Maria Condò1, Annio Posar1, Annalisa Arbizzani1 and Antonia Parmeggiani1
(1) Child Neurology and Psychiatry Unit, Department of Neurological Sciences, University of Bologna, Via Ugo Foscolo 7, 40123 Bologna, Italy
Received: 24 April 2009 Accepted: 10 July 2009 Published online: 1 August 2009
Abstract Migraine is a common disorder in childhood and adolescence. Studies on adults show the effectiveness and tolerability of riboflavin in migraine prevention, while data on children are scarce. This retrospective study reports on our experience of using riboflavin for migraine prophylaxis in 41 pediatric and adolescent patients, who received 200 or 400 mg/day single oral dose of riboflavin for 3, 4 or 6 months. Attack frequency and intensity decreased (P < 0.01) during treatment, and these results were confirmed during the follow-up. A large number of patients (77.1%) reported that abortive drugs were effective for controlling ictal events. During the follow-up, 68.4% of cases had a 50% or greater reduction in frequency of attacks and 21.0% in intensity. Two patients had vomiting and increased appetite, respectively, most likely for causes unrelated to the use of riboflavin. In conclusion, riboflavin seems to be a well-tolerated, effective, and low-cost prophylactic treatment in children and adolescents suffering from migraine.
Antonia Parmeggiani
Email: antonia.parmeggiani@unibo.it
Subscribe to:
Post Comments (Atom)
Posts
No comments:
Post a Comment